The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain

John S. McMurray,1,* Pijus K. Mandal,1 Warren S. Liao,1 Jim Klostergaard2 and Fredika M. Robertson1

1The Department of Experimental Therapeutics; The University of Texas MD Anderson Cancer Center; Houston, TX USA; 2The Department of Molecular Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA

Keywords: phosphopeptide, prodrug, SH2 domain, STAT3, peptidomimetic

Herein we review our progress on the development of phosphopeptide-based prodrugs targeting the SH2 domain of STAT3 to prevent recruitment to cytokine and growth factor receptors, activation, nuclear translocation and transcription of genes involved in cancer. We developed high affinity phosphopeptides (Ki = 46–200 nM). Corresponding prodrugs inhibited constitutive and IL-6 induced Tyr705 phosphorylation at 0.5–1 μM in a variety of human cancer cell lines. They were not cytotoxic at 5 μM in vitro but they inhibited tumor growth in a human xenograft breast cancer model in mice, accompanied by reduced VEGF expression and angiogenesis.

Signal Transducer and Activator of Transcription 3 (STAT3) is a Target for Anticancer Drug Design

Signal transducer and activator of transcription 3 (STAT3) is likely the most studied member of the STAT family of proteins.1–7 STAT3 participates in the transcription of numerous proteins and is hypothesized to play indispensable roles in the development of a large number of human cancers, metastasis, angiogenesis and immune evasion.8–10 Thus targeting STAT3 is regarded as a potential modality for the treatment of cancer.4,5,11–14 STAT3 signals by being recruited to phosphotyrosine residues on growth factor and cytokine receptors. On binding via its Src homology 2 (SH2) domain, Tyr705 becomes phosphorylated by associated JAK kinases, Src or the phosphotransferase activity of the receptor. Phosphorylated STAT3 (pSTAT3) dimerizes by reciprocal pTyr-SH2 domain interactions, is translocated to the nucleus, then acts as a transcription factor participating in the expression of acute phase response genes, vascular endothelial growth factor (VEGF), matrix metalloproteinase 9, Bcl proteins and others. Recently, other functions of STAT3 have been discovered. Unphosphorylated STAT3 was found to act as a co-transcription factor in complex with NFκB.15 In non-transcriptional roles, STAT3, phosphorylated on Ser727, was found to be located in electron-transport complexes in the mitochondria16 and in this state supported RAS transformation of cells.17 Removing STAT3 from cells using siRNA, antisense or like techniques, or overexpressing STAT3 or dominant negative versions, likely will impact multiple STAT3 functions. Precise determination of the role of Tyr705 phosphorylation can be accomplished by highly selective inhibitors targeted to the SH2 domain that block association with receptors and subsequent phosphorylation, dimerization and transcriptional activities. In this review we highlight our progress in the development of high affinity phosphopeptide ligands of the SH2 domain of STAT3, their conversion to cell-permeable, phosphatase-stable prodrugs and the evaluation of these in cellular and human cancer xenograft models of human cancer. We found that although selective inhibition of Tyr705 phosphorylation is not cytotoxic to cancer cells in vitro, in vivo tumor growth inhibition can be achieved which may be driven by reduced angiogenesis.

Targeting SH2 Domains

SH2 domains are 100 amino acid domains that recognize phosphotyrosine and two to four residues to its C-terminus.18,19 These domains are involved in the recruitment of signal transduction proteins to activated receptors of growth factors and cytokines and aberrant signaling by these pathways contributes to a variety of diseases such as cancer and asthma. The SH2 domains of Src, Lck, Grb2 and p85 were easily expressed and structures of complexes with phosphopeptides obtained by X-ray crystallography or NMR guided industrial, government and academic laboratories that developed several high affinity, elegant peptidomimetics.20–22 In spite of this great effort, there is a paucity of literature describing the
biological activity of these materials and no SH2 domain-targeted phosphopeptide mimetics have advanced to clinical trials.

Two major challenges that have impeded the development of phosphopeptide-based SH2 domain inhibitors are the negative charge of the phosphate group that prevents passive diffusion across cell membranes and the lability of the phosphate group to phosphatase activity, which renders phosphopeptides unrecognizable. To overcome phosphatase-lability, researchers have replaced phosphate groups with carboxyl, phosphonate, malonate, phosphonomethyl, phosphonodifluoromethyl and heterocyclic groups that are negatively charged.²³,²⁴ Bioreversible esters have been employed to block the negative charge of the phosphate or phosphate oxygens in a variety of compounds including SH2-domain-targeted peptides and mimetics.²⁵ The Garbay group employed S-acetylthioethyl groups on a series of phosphopeptides targeting the SH2 domain of Grb2.²⁶–²⁷ Cytotoxicity to cancer cell lines was observed at 1 μM concentration. Gay et al. employed the phenyl phosphoramide approach to deliver phosphopeptides targeting Grb2 to tumor cells,²⁸,²⁹ with concentrations -25 μM required to inhibit the target. Stankovic reported pivaloyloxymethyl (POM) protection of phosphatase-stable phosphodi-fluoromethylphenylalanine in a Src SH2 domain inhibitor.³⁰ They were only able to append one POM group to the phosphonate. Although the mono-POM prodrug entered cells, no biological evaluation was reported. McKinney et al. reported a bis-POM protected phosphonodifluoromethyl analogue of a phosphopeptide mimetic targeting STAT4 and STAT6 but no biological data were presented.³¹

Development of High Affinity Phosphopeptide Mimics Targeting the SH2 Domain of STAT3

Several groups have engaged in the development of peptidomimetic inhibitors targeting the SH2 domain of STAT3. The team of James Turkson and Patrick Gunning has developed inhibitors derived from the Tyr²⁰⁵ sequence²²–²³ and from screening and medicinal chemistry approaches.³⁴–³⁵ Others have used the Tyr²⁰⁵ sequence³⁶ as well as our lead, Peptide 1.6.³¹ To develop high affinity and selective phosphopeptides targeting the SH2 domain, our laboratory screened a set of candidates derived from putative STAT3 binding sites on receptors for IL-6, EGF, IL-10 and G-CSF and found that Ac-pTyr-Leu-Pro-Gln-Thr-Val-NH₂ (termed Peptide 1.6) from the sequence surrounding Tyr²⁰⁴ of the IL-6 co-receptor gp130, was a high affinity ligand (Fig. 1). Peptide 1.6 inhibited STAT3-DNA complex formation with an IC₅₀ = 150 nM, as judged by electrophoretic mobility shift assays.³² Wiederkehr-Adam et al. found similar peptides using a combinatorial phosphopeptide approach.³³ Peptide 1.6 possesses the pTyr-Xaa-Yaa-Gln motif reported to be the recognition determinant of STAT3.³⁴,³⁵ Substitution of the glutamine of Peptide 1.6 with alanine, glutamic acid and asparagine reduced affinity thereby supporting the requirement for glutamine at pY+3 for high affinity binding to the SH2 domain of STAT3.³²

To probe the molecular surface of the SH2 domain of STAT3 and to search for high-affinity modifications, we substituted natural and unnatural amino acids at each position of our lead peptide. We independently developed a fluorescence polarization assay to monitor the ability of phosphopeptides to compete with the N-terminally fluorescein-tagged version of Peptide 1.6 (FAM-Ala-pTyr-Leu-Pro-Thr-Val-NH₂). FAM = 4 carboxyfluorescein) for binding to full length STAT3.³⁶ Haan et al. expressed just the SH2 domain of STAT3 but it only bound a phosphopeptide at pH 5.5.³⁷ Due to potential conformational variation at the lower pH that might not exist at physiological pH, we expressed full-length protein for our assays. Peptide 1.6 exhibited an IC₅₀ of 290 nM. We utilized the truncated peptide Ac-pTyr-Leu-Pro-Thr-NH₂ (termed Peptide 3.1, IC₅₀ = 739 nM, Fig. 1) as the template for our studies. In spite of the reduced affinity of peptide 3.1, its smaller size meant significantly less synthetic steps in the mostly manual syntheses that produced the phosphopeptides we assayed. Affinity was recaptured with the modifications we incorporated. We showed that hydrophobic groups could be appended to the N-terminal nitrogen of pTyr (position pY−1) suggesting a hydrophobic patch exists on the protein surface adjacent to the phosphotyrosine binding pocket.³⁸ Leucine at pY+1 could be substituted with a variety of hydrophobic residues. Aliphatic amino acids such as norleucine and cyclohexylalanine provided higher affinity than aromatic phenylalanine.³⁹ Methylation of the nitrogen of Leu at pY+1 abrogated binding,³⁸ which supports experimentally the hydrogen bond between the NH of Leu³⁰ and the C = O of Ser³¹ observed in the crystal structure of the STAT3 dimer published by Becker, et al.³²

Alanine scanning showed that proline at position pY+2 contributed significantly to binding³² and throughout our studies 19 proline analogs were substituted at this position to probe this site.³⁶,³⁹–⁴¹ Of this group, cis-3,4-methanoproline (mPro) provided a two-fold increase in affinity and this amino acid was utilized in later structure-affinity relationship studies. Peptide bonds containing proline (Xaa-Pro) can exist either in the cis or trans conformation. Pseudoproline derivatives, 2,2-dimethyl-1,3 oxazole-4-carboxylate and 2,2-dimethyl-5-methyl-1,3 oxazole-4-carboxylate, result in predominantly cis-peptide bonds, as opposed to native proline, predominantly trans.³² Incorporation of these pseudoproline residues resulted in 63–69% cis conformation (proline, 2%) and decreased affinity 3– to 5-fold suggesting that the when bound to the SH2 domain of STAT3, Leu-Pro is in the trans conformation (Fig. 1, peptides DRCIV-5C and DRCIV-7C).³⁹

Overall, we substituted 45 Gln surrogates at pY+3 to probe the binding site.³⁶,³⁸–⁴⁵ Methyl substitutions on the side chain amide nitrogen were not tolerated and isosteric methionine sulfoxide resulted in a > 10-fold loss in affinity.³⁶ These results indicated the importance of hydrogen bond donation by the side chain amide group of Gln. Various cyclic and aliphatic glutamine surrogates were tolerated with slight losses in affinity.³⁸,³⁹–⁴⁵

Threonine at pY+4 was replaced with a variety of groups: organic, heterocyclic and peptidic.³⁷,³⁸ The most effective substitution was a simple benzylamide.³⁶ Taking these lessons into account, we incorporated a hydrophobic N-terminus, mPro, and a C-terminal benzyl amide to create SMI-48B2 (Fig. 1), which had an IC₅₀ of 125 nM, a five-fold increase in affinity over Peptide 3.1.
A

Peptide 1.6: Ac-pTyr-Leu-Pro-Gln-Thr-Val-NH₂
IC₅₀: EMSA, 150 nM; FP, 290 ± 63 nM

Peptide 3.1: Ac-pTyr-Leu-Pro-Gln-Thr-NH₂
IC₅₀ = 739 ± 41 nM

DRCIV-5C: R = H; cis 69%; IC₅₀ = 3830 ± 125 nM
DRCIV-7C: R = CH₃; cis 63%; IC₅₀ = 2070 ± 164 nM

PM-50D: IC₅₀ = 136 ± 23 nM

SMI-48B2: IC₅₀ = 125 ± 27 nM

DRCIV-35B: IC₅₀ = 231 ± nM

PM-235E, R = H IC₅₀ = 51 ± 5 nM
SMI-247B2, R = CH₃ IC₅₀ = 35 ± 5 nM

B

C

X  R  Kᵢ (nM)
PM-228F  CH₂  CH₃  66 ± 13
PM-229F  O  H  114 ± 14
PM-233F  NH  H  46 ± 6
Conformationally Constrained Phosphopeptides

Properly constrained peptide inhibitors can lead to increased affinity by presenting the contact groups in the proper orientation for binding to the target protein. By constraining the molecule to the bioactive conformation, the system does not lose the entropy of rotation of all of the peptides’ bonds on binding, leading to a favorable entropic term in the free energy equation. The dihedral angle of C-C$_\alpha$-C$_\beta$-C$_\gamma$ of the phosphotyrosine residue in the STAT3 crystal structure is 174 degrees. The phosphotyrosine mimic, 4-phosphoryloxycinnamate (pCinn), constrains this angle to 180° and resulted in a 5-fold increase in affinity of peptide 3.1 (PM-50D, IC$_{50}$ = 136 nM, Fig. 1). Interestingly, pCinn resulted in a 11-fold loss in affinity for a phosphopeptide inhibitor of the Src SH2 domain. Examination of the crystal structure of STAT3 bound to DNA as well as models generated by us led to the hypothesis that addition of a methyl group on the β-carbon of pTyr or pCinn would lead to greater hydrophobic interaction with the side chain methylene groups of Glu, which lines the phosphotyrosine binding pocket. We developed synthetic methodology for β-methylcinnamate and found that this substitution increased affinity 1.5–3 fold in a series of peptides (e.g., PM-235E vs. SMI-247B2, Fig. 1).

To constrain the central dipeptide, Leu-Pro was substituted with a series of azabicyclo[4.3.0]-nonane-9-carboxylates (ABN), in which the side chain of leucine was incorporated in a 6-membered ring fused to the 5-membered ring of proline. All stereoisomers of this bicyclic lactam reduced activity. However, substitution with the tricyclic heterocycle, Haic, increased affinity of our peptides > three-fold (DRCIV-35B, IC$_{50}$ = 231 nM, Fig. 1). Chen et al. incorporated azabicyclo[6.3.0]undecane (ABU) and found that this substitution increased affinity 20-fold. All of these dipeptide replacements constrain the ψ dihedral angle of the pY+1 residue. The size of the ring fused to the five-membered ring of proline is important. The eight-membered ring in ABU appears to allow the most optimal orientation of the Gln with respect to the phosphotyrosine, as compared with the seven-membered ring of Haic and the six-membered ring of ABN.

Constrained peptidomimetics exhibited high affinity. Among the more notable candidates were a series containing glutamine surrogates (R)-4-aminopentamide, in which the α-carboxyl group of Gln was reduced to a methyl group (PM-228F, K$_t$ = 66 ± 13 nM), straight chain ethylcarbamate (PM-229F, K$_t$ = 114 ± 14 nM) and a straight chain ethylurea (PM-233F, K$_t$ = 46 ± 6 nM) (Fig. 1).

Structure of Phosphopeptides Bound to the SH2 Domain of STAT3

Structures of protein-ligand complexes are extremely useful in drug development programs. Unfortunately, STAT3 was difficult to crystallize and in the one structure we obtained, the electron density for the peptide (PM-50D) was too weak to determine its structure. However, molecular modeling approaches provided some insights of phosphopeptide-SH2 domain interactions. In the first model we examined potential interactions between the phosphopeptide, Ac-pTyr-Leu-Pro-Gln-NHBn, and STAT3 using the structure of a phosphopeptide complexed with STAT1 as a template. This model showed three hydrogen bonds between the Gln CONH$_2$ of the inhibitor and the protein, highlighting the importance of this residue for recognition and affinity (Fig. 1B). In the second, docking and molecular dynamics simulations of the peptidomimetic inhibitor, pCinn-Haic-Gln-OH, showed that the glutamine binds in a slightly different pocket (Fig. 1C). A loop of STAT3 (residues 659–668) moves so that Met660 forms a hydrophobic interaction with the five- and six-membered rings of Haic. The main chain NH of Met660 hydrogen bonds with the OH of Tyr, which is involved with a hydrogen bond with the C = O of Haic.

Inhibition of STAT3 Phosphorylation in Intact Cells and Development of Phosphopeptide Mimic Prodrugs

To inhibit STAT3 phosphorylation in intact cells we employed a prodrug approach. The phosphate was replaced with the phosphatase-stable phosphonodifluoromethyl group. The negative charge of the phosphonate oxygens was blocked with the pivaloyloxymethyl group (POM), which is cleaved by carboxyl esteras (Fig. 2A). Our first prodrug, BP-PM6 (Fig. 2A), inhibited constitutive phosphorylation of STAT3 in human MDA-MB-468 breast tumor cells at a concentration of 10 μM, supporting the hypothesis that the compound entered the cells, was stripped of its POM groups by esterases and bound to the SH2 domain of STAT3, preventing receptor recruitment and phosphorylation of Tyr. The reduction of pSTAT3 also suggests that STAT3 is phosphorylated and dephosphorylated in a dynamic equilibrium, which we can perturb with phosphopeptide mimics.

We converted several phosphopeptide mimetics into cell-permeable prodrugs (Fig. 2B). Although the range in affinity of the phosphate bearing root structures was within a factor of 3, the structures of these prodrugs had a striking effect on potency of inhibition of constitutive pSTAT3 in intact MDA-MB-468 cells in culture. Addition of a methyl group to the β-position of the cinnamoyl moiety produced a slight increase in potency (BP-PM6 vs. PM-70G and PM-299G vs. PM-73G, Fig. 2C), which reflected the increase in affinity of the corresponding phosphopeptides for STAT3. Interestingly, the potency of prodrugs in which the C-terminal benzylamide group (CONHC$_2$H$_4$) was replaced by a simple methyl group was enhanced > 10-fold (BP-PM6 vs. PM-299G and PM-70G vs. PM-73G, Fig. 2C). This was not
Fig. 2 (See previous page). Inhibition of the phosphorylation of STAT3 Tyr705 in intact cells. (A) Prodrug strategy showing the phosphatase-stabilizing CF3 substitution and the POM blocking groups. Cleavage of the POM groups liberates the negatively charged phosphate for binding to the SH2 domain of STAT3. (B) Structures of prodrugs used to study STAT3 phosphorylation. (C) Inhibition of constitutive Tyr705 phosphorylation in MDA-MB-468 breast cancer cells. The left column shows the effect of addition of a methyl group on the β-position of the cinnamate (BP-PM6 vs. PM-70G and PM-299G vs. PM-73G) and the increase in potency on substituting the CONBn group with a simple methyl group (BP-PM6 vs. PM-299G and PM-70G vs. PM-73G). The center column shows inhibition by the Nle-mPro-containing prodrugs PM-72G-1 and PM-274G-1 and the reduced potency of the stereoisomers possessing “D” mPro. The right column shows the time course of inhibition of Tyr705 phosphorylation (5 μM prodrug) and the dose response of the prodrug of one of the highest affinity phosphopeptides, PM-173G. Gels are presented in pairs in which the upper is pTyr705-STAT3 and the lower is total STAT3. With the exception of the time course study, cells were exposed to prodrugs for 2 h before lysis and protein determination by western blots.

reflective of the intrinsic affinity of the corresponding phosphopeptides in which the benzylamide-containing peptides were 2-fold more avid than the corresponding methyl substituted peptides. Replacing the CONHBn with an isosteric ether CH(CH3)OBn resulted in highly potent inhibition of constitutive pSTAT3 (PM-72G-1). Replacement with a methyl group retained the potency in cells (Fig. 2C, PM-72G1 vs. PM-274G-1) whereas in the corresponding phosphopeptides the CH(CH3)OBn resulted in slightly more affinity for isolated STAT3 (2.5-fold) than the methyl group. Prodrugs containing mPro were very highly potent inhibitors of STAT3 phosphorylation (PM-72G-1 and PM-274G-1, Fig. 2C). As mPro is no longer commercially available and its synthesis by any of the reported methods is expensive and low yield, we sought less expensive proline derivatives. In a prodrug containing native proline (PM-296G, Fig. 3A), complete inhibition occurred at 10 μM. However, prodrugs containing the substituted prolines, mPro, 4,4-dimethylproline and 4,4-difluoroproline were all significantly more potent. Complete inhibition occurred at 500 nM. It is unclear at this time why this difference occurs. However, one could speculate that there may be proteolysis of the proline peptide and that the substituted prolines may not fit in the active site of the putative protease.

Three prodrugs, PM-73G, PM-274G and PM-72G, were studied in detail (Fig. 2B). These compounds had β-methyl cinnamyl amide and were varied at both the central dipeptide and the glutamine surrogate. After a two-hour exposure of MDA-MB-468 cells, significant inhibition of constitutive phosphorylation of STAT3 was observed at 100 nM and complete inhibition occurred at 500 nM (Fig. 2C). Commercially available mPro is a mixture of “L” and “D” enantiomers, and in the cases of PM-72G and PM-274 two prodrugs were isolated in the synthesis, designated with either a -1 or -2 to reflect the order of elution from the preparative HPLC. The second stereoisomers were much less potent, requiring 25 μM for complete inhibition, which reflects the relative affinities of the phosphopeptides. Time course experiments showed significant inhibition at 30 min with recovery of pSTAT3 at about 8 h. These materials inhibited Tyr705 phosphorylation in a variety of human cancer cell lines including U266 (multiple myeloma), MDA-MB-231, SUM190, SUM 149 (breast), HCC-827 (lung) and SKOV3-ip (ovarian). They also inhibited IL-6 stimulated phosphorylation in MeWo and A375 (melanoma) and HeyA8 (ovarian) cells.

Based on similarity of binding free energies of phosphopeptides to a set of SH2 domains, Ladbury and colleagues postulated that selective inhibition of SH2 domains within cells is unlikely. To test this hypothesis, we assayed for the effect of our STAT3 inhibitors on the activities of SH2 domain-driven pathways. Administration of epidermal growth factor (EGF) to MDA-MB-468 cells resulted in phosphorylation of STAT5. Our prodrugs did not inhibit that process, suggesting that they do not bind appreciably to STAT5 (Fig. 3B). Phosphatidylinositol-3-kinase is recruited to receptors via the SH2 domains of the p85 regulatory domain, which activates the kinase domain leading to the phosphorylation of Akt. Our prodrugs did not inhibit constitutive Ser673 phosphorylation, suggesting that they did not bind to p85 (Fig. 3B). Via its SH2 domain, Src kinase binds to the focal adhesion kinase and selectively phosphorylates Tyr416. Our prodrugs did not impact this process indicating selectivity for STAT3 over Src (Fig. 3C). Significant inhibition of interferon-γ stimulated phosphorylation of STAT1 was observed at 1 μM but 5 μM was required for complete inhibition (Fig. 3D). These are 10-fold higher concentrations that observed for the inhibition of pSTAT3. The amino acid sequences and the three dimensional structures of the phosphopeptide binding regions of STAT1 and STAT3 are nearly identical, so cross reactivity is not surprising. However, at high concentration (25 μM) selectivity for STAT3 over these processes was abolished.

These results suggest that it is indeed possible to dial in specificity for specific SH2 domains in intact cells, but concentrations must be carefully regulated. Two features of our peptides contribute to the selectivity for the SH2 domain of STAT3: (1) the cinnamic acid-derived pTyr mimic, which reduced affinity for the Src SH2 domain and (2) the glutamine surrogate. Most SH2 domains, e.g., Src, p85 and STAT5, recognize hydrophobic residues at pY+3 and the hydrophilic side chain amid of the Gln mimic would not be accommodated in these binding pockets. The Ladbury analysis focused on the SH2 domain of Src.

Effect of STAT3 Inhibition on the Growth and Survival of Cancer Cells In Vitro

The possible linkage between STAT3 phosphorylation inhibition and cell survival has been a point of marked controversy based on many studies. Our efforts have for the first time provided effective tools for dissecting these responses and reveal them as distinct. We examined the effect prodrugs on proliferation of MDA-MB-468 breast cancer cells using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium (MTT) or sulforhodamine B (SRB) assays. PM-73G, PM-274G-1 and PM-274G-2 showed little or no ability to inhibit growth up to 50 μM (Fig. 4A), which is a concentration
100 times that at which constitutive pSTAT3 was completely inhibited. However, both stereoisomers of PM-72G inhibited growth at with an IC$_{50}$ of $10^{-15}$ M. Since PM-72G-2, which contains the “D” stereoisomer of mPro and required $25 \text{ mM}$ to inhibit pSTAT3, also inhibits cell growth, it is likely that inhibition by both of the PM-72G versions is due to off-target effects due to the C-terminal Gln-benzyl ether group, which is missing in structural analog PM-274G and in PM-73G. Realizing that levels of pSTAT3 recover after about eight hours following exposure to prodrug, assays were repeated with daily administration of PM-73G and PM-72G-1 (Fig. 4B). The IC$_{50}$ for PM-73G was between 25 $\mu$M and 50 $\mu$M, which is 50 times higher than the 0.5 $\mu$M concentration that completely inhibited pSTAT3. Growth and survival assays were also performed on multiple tumor cell lines including melanoma (A375 and MeWo), lung (HCC-827, H1299, H1819, H520 H528 and A549), breast (MCF7, MDA-MB-231, SUM190 and SUM149), ovarian (SKOV3-ip) and multiple myeloma (U266) cells, again with no appreciable toxicity detected at 5 $\mu$M. A direct comparison of MCF7 cells (no constitutive pSTAT3) and SKOV3-ip, HCC-827 and MDA-MB-468 cells (constitutive pSTAT3) with daily administration of PM-73G revealed no correlation between STAT3 phosphorylation and cytoxicity (Fig. 4C). No inhibition of cyclin D1 or Bcl protein expression at 5 $\mu$M of PM-73G, PM-72G-1 or PM-274G-1 was observed. PM-7G does not have cleavable phosphonate blocking groups and it displays minimal effect on survival of MCF7, SKOV3-ip, HCC-827 and MDA-MB-468 cells (Fig. 4D). Thus the cinnamoyl-Haic-Apa sub-structure is not cytoxic on its own and the phosphonate contributes to the observed cell death.

At the relatively high concentration of 25 $\mu$M in MDA-MB-468 cells, PM-73G inhibited phosphorylation of FAK pTyr861 and Akt Ser473 after two hour treatment, as well as EGF-stimulated STAT5 phosphorylation (Fig. 4E). Thus, at high concentrations, selectivity for individual SH2 domains is compromised and cytoxicity correlates with off-target effects.

Collectively, these results challenge the hypothesis that Tyr$^{705}$ phosphorylation of STAT3 is required for cell growth and
proliferation in vitro. Further challenges come from inhibition of pSTAT3 by JAK kinase inhibitors. The first example came from Kreis et al., who noted that treatment of several melanoma lines with Pyridone 6 completely inhibited STAT3 phosphorylation but had no impact on cell growth. Hedvat et al. reported that the JAK2 inhibitor, AZD1480, at concentrations that completely inhibited pSTAT3, had no effect on the proliferation of MDA-MB-468 (breast), DU145 (prostate) and MDAH2774 (ovarian).
cancer cells in vitro. This was reported in subsequent publications from this group and others. Looyenga et al. found that the JAK1/2 inhibitor ruxolitinib did not affect growth of lung cancer cell lines in vitro. Treatment of ovarian cancer cells with the anti-IL-6 monoclonal antibody siltuximab inhibited STAT3 phosphorylation but did not affect proliferation of cells grown on plastic as adherent cultures. Thus it would appear that selective inhibition of Tyr705 phosphorylation is not cytotoxic to cancer cells of epithelial origin in vitro. Furthermore, if an agent or compound is killing these cells, it is acting by off-target effects. Controversy still exists as Zhang et al. recently reported that an apparently selective small molecule (not a phosphopeptide mimic) targeting the SH2 domain of STAT3 displays cytotoxicity in vitro.

**Effect of Selective STAT3 Inhibition In Vivo**

In spite of the lack of cytotoxicity, we evaluated the ability of PM-73G to inhibit tumor growth in vivo using the MDA-MB-468 breast tumor model. In an initial intratumoral (IT) administration trial, we found that tumor growth was inhibited which was accompanied by a reduction in tumor microvessel density and VEGF protein. IT administration of concentrations as low as 8 uM resulted in inhibition of pSTAT3 in tumor sections as determined by immunohistochemical staining of tumor sections using anti-pSTAT3 antibodies.

To determine the utility of systemic administration, mice bearing MDA-MB-468 tumors were treated with 170 mg/kg of PM-73G administered intraperitoneally (i.p.) daily for 5 d followed by two days rest over four weeks. Rodents have circulating carboxyesterases which prematurely deprotect the POM group, thus necessitating such a high dose. Tumors from the treated animals grew at much lower rates than those given the vehicle (20% Trappsol/PBS) (Fig. 4F). Immunohistochemical analysis revealed nearly complete inhibition of vascularization. Two hours after administration of PM-73G pSTAT3 levels were significantly reduced, compared with vehicle (Fig. 4F). Thus selectively inhibiting STAT3 phosphorylation impedes communication with the microenvironment, i.e., VEGF signaling and angiogenesis. Necropsy examination revealed no organ toxicity and no changes in complete blood counts (cbs). To the best of our knowledge, this is the first example of a phosphopeptide-based prodrug targeting an SH2 domain showing the ability to inhibit its target by systemic administration. This contrasts with the compounds of Zhang et al., which utilize carboxyphenyl groups to target the phosphotyrosine binding pocket.

Of the four cell lines examined in Figure 4C, MDA-MB-468 was the most sensitive to growth inhibition in vitro. The others were not evaluated in vivo so it is unclear if the observed reduction in tumor growth and microvessel density is cell line-dependent. However, our results are similar to those recently reported for JAK2 kinase inhibitors AZD1480 and ruxolotinib that employed other cell lines. Whereas inhibition of STAT3 phosphorylation is not intrinsically cytotoxic, anti-tumor activity is the result of impaired communication between tumor cells and the microenvironment, e.g., VEGF production and activity. AZD1480 impacts immune cell recruitment to the tumor, supporting the proposed role(s) of STAT3 in immune surveillance and tumor immunity.

### Synthesis of Amino Acid Surrogates and Peptidomimetics

The structure-affinity and structure-activity studies described in this communication utilized phosphotyrosine, Leu-Pro dipeptide and glutamine surrogates that were not available commercially. Synthetic strategies had to be developed for these materials which was a major part of the program. Readers are referred to references 46, 54 and 55 for the synthesis of glutamine mimics; 49, 50, 51 and 58 for the synthesis of pseudoproline peptides; Leu-Pro mimics and proline analogs; 50, 53 and 63 for constrained tyrosine mimics; and 53 and 63 for the synthesis of the prodrugs.

### Summary

At the outset of the program our laboratory had two goals: (1) to develop cell-permeable phosphopeptide mimics targeting an SH2 domain and (2) to use this technology to inhibit an important cancer target, STAT3. Our chemistry effort developed very high affinity phosphopeptides and were able to convert these into prodrugs which hit their target in vivo with systemic (ip) administration. Our data and that of Zhang et al. suggest that the SH2 domain is indeed druggable, despite the failed attempts of the industrial, government and academic labs mentioned above. As mentioned, the bis-POM prodrug strategy is useful for proof of principle studies, but it suffers from premature loss of one of the POM groups due to both esterase activity and chemical hydrolysis. Improvements to the bioreversible ester strategy are ongoing. Although we do not have a clinical candidate as of yet, our selective phosphopeptide mimics have been useful tools for the study of Tyr705 phosphorylation. From our work and the studies of the JAK inhibitors, the dogma of STAT3 signaling is shifting. For epithelial tumors, it appears that phosphorylated STAT3 is not necessary for tumor cell survival. However, the original studies on the effects of STAT3 on VEGF expression and signaling have borne true. Inhibition of STAT3 Tyr705 phosphorylation appears to be a new antiangiogenesis strategy.

### Acknowledgments

We are especially grateful to Dr Timothy Schaefer who got us started on the STAT3 program. His departure from the MD Anderson Cancer Center was a setback for JAK-STAT science. We are grateful to the MD Anderson Cancer Center that provided us the seed money, which led to funding by the NCI, RO1 CA096652. We acknowledge the MDACC SPOR in ovarian Cancer P50 CA083639, the UT SPOR in lung cancer P50 CA070907 and the MDACC SPOR in Melanoma, P50 CA093459 and the CTT/TI-3D Chemistry and Molecularly-Targeted Therapeutic Development Grant Program for support of this work and the NCI Cancer Center Support Grant CA016672 for the support of our NMR facility and the Translational Chemistry Core Facility for mass spectrometry and X-ray crystallography. We are grateful to Dr Xiaomin Chen and Dr Zhiyong Ren who expressed copious amounts of STAT3 and who crystallized the protein.
4. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008; 15:834-43; PMID:18475733; http://dx.doi.org/10.2174/09298670878355464

5. Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008; 3:1159-68; PMID:18683176; http://dx.doi.org/10.1002/cmdc.200800123

6. Levy DE, Darnell JE, Jr., Stat: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:5-6; PMID:11994401

7. Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105; PMID:14694307; http://dx.doi.org/10.1038/nrc1275

8. Liu WQ, Shi S, Lepom K, Figura RA, Yu H, Stat3: a target to enhance antitumor immune response. Curr Top Microb Immunol 2011; 344:41-59; PMID:20517723; http://dx.doi.org/10.1007/1082_2010_51

9. Korrêywski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008; 20:228-33; PMID:18479894; http://dx.doi.org/10.1016/j.coi.2008.03.010

10. Yu H, Pardoll D, Jove R. Stat3 in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19581535; http://dx.doi.org/10.1038/ncl274

11. Hafchencyn S, Awadisian M, Gunning PT, Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anticancer Drugs 2011; 22:115-27; PMID:21751940; http://dx.doi.org/10.1097/CCD.0b013e328341185b

12. Lavecchia A, Di Giovanni C, Novellino E. STAT3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011; 18:2359-75; PMID:21568920; http://dx.doi.org/10.2174/0929867117938218

13. Mankan AK, Gretten FR. Inhibiting signal transducer and activator of transcription 3: rationale and rational design of inhibitors. Expert Opin Investig Drugs 2011; 20:1263-75; PMID:21751940; http://dx.doi.org/10.2174/13895852011153010

14. Berg T. Signal transducers and activators of transcription as targets for small organic molecules. ChemBioChem 2008; 9:2039-44; PMID:18677740; http://dx.doi.org/10.1002/cbic.200800274

15. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. G3:8 Review 2008; 18:443-51; PMID:18666677; http://dx.doi.org/10.1383/g3.2008.41

16. Wegrzyn J, Poria R, Chaoa YJ, Sepuri NB, Zhang Q, Koek T, et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009; 323:793-7; PMID:19135194; http://dx.doi.org/10.1126/science.1164551

17. Gough DJ, Coelert A, Schlesinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial Stat3 supports Ras-dependent oncogenic transformation. Science 2005; 309:1715-8; PMID:15956608; http://dx.doi.org/10.1126/science.1117722

18. Pawson T. Protein modules and signalling networks. Nature 1995; 373:573-80; PMID:7531822; http://dx.doi.org/10.1038/373573a

19. Waksman K, Kumaran S, Lubman O. SH2 domains: role, structure and implications for molecular medicine. Expert Rev Mol Med 2004; 6:1-18; PMID:14987453; http://dx.doi.org/10.1017/S1462393904007331
58. Mandal PK, Kaluarachchi KK, Ogrin D, Bott SG, McMurray JS. Structural basis for the binding of high affinity phosphopeptide ligands for the Stat3
core fragment. Biochim Biophys Res Commun 2008; 374:1-5; PMID:18433722; http://dx.doi.org/10.1016/j.brc.2008.04.049

59. Mandal PK, Liao WS, McMurray JS. Synthesis of phosphatase-stable, cell-permeable phosphopeptide mimetics that target the SH2 domain of Stat3. Adv Exp Med Biol 2009; 611:387-393; PMID:19354123; http://dx.doi.org/10.1007/bf00187015

60. Mandal PK, Heard PA, Ren Z, McMurray JS. Solid-phase synthesis of Stat3 inhibitors incorporating O-carboxyaminoxy and O-carboxalanylthreonine as glutamic acid mimetics. Bioorg Med Chem Lett 2007; 17:6549-54; PMID:17940305; http://dx.doi.org/10.1010/7/978-0-88-73657-0_238

61. Mao X, Ren Z, Parker GN, Sondermann H, Pastorello PP, Wolf G, et al. Nonhydrolyzable phosphotyrosyl phosphopeptide mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry 1994; 33:6490-4; PMID:7515682; http://dx.doi.org/10.10107/bio/00187015

62. Farquhar D, Khan S, Srivastva DN, Saunders PP. Structure and antitumor evaluation of bis[[pivaloyloxy]methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP), a strategy to introduce nucleotides into cancer cells. J Med Chem 1994; 37:3902-9; PMID:7966151; http://dx.doi.org/10.1021/jm00049a009

63. Fujimoto Y, Irrevere F, Karle JM, Wirkop B. Synthesis and x-ray analysis of cis-3,4-methylene-L-proline, the new natural amino acid from horse chestnuts, and of its trans isomer. J Am Chem Soc 1971: 93:3471-7; PMID:5103572; http://dx.doi.org/10.1021/ja06743a030

64. Sagnard I, Suski NA, Chiaroni A, Riche C, Potier P. Enantioselective Synthesis of Cyclopropene A-Amino Acids: Synthesis of N-Boc-cis-[[2S,3S,4S].3,4-Methanophenol and N-Boc-[[2S,3R,4S]-3,4-Methanoglutamic Acid. Tetrahedron Lett 1995; 36:3149-52; PMID:19334714; http://dx.doi.org/10.1021/ja00187a015

65. Sagnard I, Suski NA, Chiaroni A, Riche C, Potier P. Enantioselective Synthesis of Cyclopropene A-Amino Acids: Synthesis of N-Boc-cis-[[2S,3S,4S].3,4-Methanophenol and N-Boc-[[2S,3R,4S]-3,4-Methanoglutamic Acid. Tetrahedron Lett 1995; 36:3149-52; PMID:19334714; http://dx.doi.org/10.1021/ja00187a015

66. Calalb MB, Zhang X, Polte TR, Hanks SK. Focal adhesion kinase tyrosine-816 is a major site of phosphorylation by Src. Biochem Biophys Res Commun 1996; 226:662-8; PMID:8941136; http://dx.doi.org/10.1016/0006-291X(96)80877-3

67. Muller J, Schust J, Berg T. A high-throughput assay for signal transducer and activator of transcription 5 based on fluorescence polarization. Anal Biochem 2008; 375: 249-54; PMID:18258175; http://dx.doi.org/10.1016/j.ab.2008.01.017

68. Kreis S, Munz GA, Haan S, Heinrich PC, Behrmann I. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res 2007; 5:1331-41; PMID:17187199; http://dx.doi.org/10.1158/1541-7786.MCR-07-0317

69. Hedvat M, Huzar D, Herrmann A, Gozgit JM, Schroder A, Sheepy A, et al. The JAK2 inhibitor AZD480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16:487-97; PMID:19962667; http://dx.doi.org/10.1016/j.ccr.2009.10.015

70. Scuto A, Kreij P, Popplewell L, Wu J, Wang Y, Kujawski M, et al. The novel JAK inhibitor AZD480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011; 25:538-50; PMID:21645517; http://dx.doi.org/10.1038/leu.2010.289

71. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD480. Cancer Res 2011; 71:6601-10; PMID:21920898; http://dx.doi.org/10.1158/0008-5472.CAN-11-1217

72. Looyenga BD, Hutchings D, Chen K, Kingley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One 2012; 7:e30820; PMID:22315950; http://dx.doi.org/10.1371/journal. pone.0030820

73. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17:6083-96; PMID:21795409; http://dx.doi.org/10.1158/1078-0432.CCR-11-0945

74. Auerenne EJ, Klontzgaard J, Mandal PK, Liao WS, Lu Z, Gao F, et al. A phosphotyrosine mimetic prodrug targeting the SH2 domain of STAT3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol 2012; In press.

75. Niu G, Wright KL, Huang M, Song L, Haura E, Turkoz J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000-8; PMID:11960372; http://dx.doi.org/10.1038/sj.onc.1205260

76. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watschow SS, et al. HIF-1alpha, STAT3, CBP/p300 and Rel-A/PAE are components of a transcriptional complex that regulates dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24:3110-20; PMID:1575682; http://dx.doi.org/10.1038/sj.onc.1208513